Processing
Processing. Please wait...

Biogen insider: Gregory Covino

 
 All Insiders  
 
Summary
PerformanceFundamentalsTechnicalsRecomendation
   Summary
   History
   Headlines
   Leaders
   Widgets

Chief Accounting Officer, Vice President - Finance

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. since April 2012. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 48  President Since 2012      
617-679-2000  http://www.biogenidec.com
Gregory Covino Education
Covino received his B.S. in Business Administration from Bryant University.

Management Efficency

The company has return on total asset (ROA) of 20.0 % which means that it generated profit of $20.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 31.54 % meaning that it created $31.54 on every $100 dollars invested by stockholders.
The company currently holds 583.93 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 2.65 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 7,550 people.

Filter other executives

Tenure
Industry  
Click to run this filter
 
Filter Other Insiders
 

Showing few of many executives

PRESIDENT Since

Cynthia PattonAmgen Inc
2012
Fong ClowPharmacyclics Inc
2012
Vikas SinhaAlexion Pharmaceuticals Inc
2012
G DavisBioMarin Pharmaceutical Inc
2005
Tuomo PatsiCelgene Corporation
N/A
Amit SachdevVertex Pharmaceuticals Incorpor
2014
Thomas ConnollyVertex Pharmaceuticals Incorpor
2013
Nicholas NaclerioIllumina Inc
2014
Daniel PlewRegeneron Pharmaceuticals Inc
2008
Daniel SpiegelmanBioMarin Pharmaceutical Inc
2012
Scott SmithCelgene Corporation
2014
Richard RanieriBioMarin Pharmaceutical Inc
2013
Robert TerifayRegeneron Pharmaceuticals Inc
2007
Tina NovaIllumina Inc
2014
Rainer ErdtmannPharmacyclics Inc
2013
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Saqib IslamAlexion Pharmaceuticals Inc
2013
Dana LeePharmacyclics Inc
2013
David PiacquadAmgen Inc
2014
Julie ONeillAlexion Pharmaceuticals Inc
2015
Carsten ThielAlexion Pharmaceuticals Inc
2014
SymbolBIIB
ISINUS09062X1037
CUSIP09062X103
NameBiogen Idec Inc
InstrumentUSA Stock
Analyst ConsensusBuy 20 Opinions
Risk-adjusted AdviceHold Under Valued
Average Bond RatingBBB Adequate
CurrencyUSD - US Dollar
ExchangeNASDAQ
DescriptionBiogen Inc. discovers develops manufactures and markets therapies for the treatment of neurological autoimmune and hematologic disorders in the United States and internationally. more
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Idec Inc to your portfolio

Biogen Idec Leadership

Lynn Schenk, Director
Steven Holtzman, President
Adriana Karaboutis, President
Paul Clancy, CFO, MBA
John Cox, EVP, MBA
Gregory Covino, President
Paul MBA, CFO
Robert Pangia, Director
Eric Rowinsky, Director, Ph.D
Douglas Williams, EVP
Caroline Dorsa, Director
Stuart Kingsley, EVP
MD, MBA, SVP
Richard Mulligan, Director
Stelios Papadopoulos, Chairman, Ph.D
George Scangos, CEO, Ph.D
Alexander Denner, Director
Brian Posner, Director
Stephen Sherwin, Director, Ph.D
Susan Alexander, President
Adriana MS, EVP
Kenneth Pietro, President
MD, Sandrock, SVP
Tony Kingsley, President, MBA
Matt Griffiths, President
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Adam Koppel, President, MBA
Spyros Artavanis-Tsakonas, President, Ph.D

Stock Performance

Shares Outstanding235.23 M
Number of Shares Shorted2.54 M